The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov
Ethics application status
Heart Failure (HF) Outpatient Monitoring Evaluation (HOME) Study
HF Outpatient Monitoring Evaluation (HOME) Study
Universal Trial Number (UTN)
Systolic Heart Failure
Acute Decompensated Heart Failure
Coronary heart disease
Other cardiovascular diseases
Description of intervention(s) / exposure
Other interventions - Interventions with heart failure medications
Experimental: BNP + Health Management - Subjects will provide information from home regarding weight,signs and symptoms, and will perform BNP self testing. This information including BNP results will be used by the investigator as an aid to treatment decisions. BNP results are blinded to subjects.
Active Comparator: Health Management - Subjects will provide information from home regarding weight, signs and symptoms, and will perform BNP self testing . BNP results will be blinded to the investigator and subject; weight, signs and symptoms will be used by the investigator as an aid to treatment decisions
Placebo Comparator: Control - Subject will provide information from home regarding weight, signs and symptoms and will perform BNP self testing. All these data will be blinded to the investigator. BNP results will be blinded to the subject.
Other interventions: Interventions with heart failure medications
Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
Intervention code 
Comparator / control treatment
Primary outcome 
Average number of "hard' events per subject - With hard events defined as:
HF related death,
HF related readmissions to the hospitaL,
IV treatment with diuretics or unusual oral diuretic change in ER
Unplanned outpatient treatments for decompensated HF
Key inclusion criteria
1. Adults (18 years of age and <75 years of age); AND
2. Admitted to the hospital or treated in an outpatient clinic with a diagnosis of
decompensated HF for which treatment will be administered;
i. BNP > 300 pg/mL (or NT-pro-BNP > 1500 pg/mL) during hospital admission or clinic visit.
OR c. Seen in an outpatient setting (i.e. heart failure clinic, general practice or
cardiology office, urgent care unit) with a documented history of HF and with signs of
worsening HF condition or decompensation, where worsening HF condition is defined as one or
more of the following;
i. Increase in NYHA class with worsening symptoms (i.e. dyspnea, fatigue) at same level of
activity ii. Symptoms requiring change in dosage of one or more of the following
2. beta blocker
3. ACE inhibitor iii. Physical evaluation consistent with worsening HF signs (i.e.
elevated JVP, ankle edema, dyspnea, abdominal distension, >4 lb or >1.8 kg weight
increase in past week) iv. HF admission in last 30 days with a documented BNP > 300
pg/mL (or NT-pro-BNP > 1500 pg/mL) during or since admission AND d. Presence of left
ventricular systolic dysfunction (ejection fraction <40%); e. Successfully trained and
deemed proficient on how to perform a fingerstick and to use the Test System. Each
subject will undergo two proficiency assessments.
i. The first assessment will be performed at the time in which the subject is found to
meet the inclusion criteria, and deemed willing, able and reliable to complete the
study tasks, and following initial training on the use of the test system. Successful
completion of this first proficiency assessment will result in the enrolment of the
subject into the study.
The second assessment will be performed following one week (7 days ± 2 days) of home
testing to demonstrate retention of the training. Successful completion of this second
proficiency assessment will result in randomization of the subject into one of the
three study arms of the study. Failure to demonstrate proficiency at this second
assessment will result in the withdrawal of the subject from the study.
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Unwilling or unable to provide written informed consent;
2. Acute coronary syndrome (ACS) that is a primary diagnosis; or secondary diagnosis
that is concomitant with the primary diagnosis of decompensated HF and for which
treatment will be provided.
Note: A history of ACS is not cause for exclusion if it is not concomitant with
the present decompensated HF for which admission is being made. Small elevations
in cardiac troponin that are considered by the treating physician to be
associated with myocardial injury due to the acute decompensated HF and not due
to a concomitant ACS or myocardial infarction are not a basis for exclusion.
3. Previous cardiac transplantation - or cardiac transplantation anticipated within
4. Current or planned use of a left ventricular assist device (LVAD), use of
outpatient intravenous inotropic HF therapy, major surgical procedure or
percutaneous coronary intervention within 3 months;
5. Life expectancy less than 6 months due to causes other than HF or cardiovascular
disease (e.g., cancer);
6. End stage renal disease (dialysis dependency);
7. Receiving any investigational medication;
8. Hematocrit outside the 25 to 50% range of the HeartCheck system;
9. Prisoner or other institutionalized or vulnerable individual;
10. Dementia, tremors or other impediments to performing daily home BNP testing via
fingerstick (unless BNP testing will be conducted by qualified caregiver);
11. Deemed by the investigator not to be likely to comply with study-mandated
procedures or instructions;
12. Residence in regions where either transmission of test system data or home visits
are not possible.
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment
Methods used to generate the sequence in which subjects will be randomised (sequence
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
Statistical methods / analysis
Reason for early stopping/withdrawal
Accrual to date
Recruitment hospital 
Royal Brisbane and Women's Hospital - Herston
Recruitment postcode(s) 
Primary sponsor type
Ethics application status
The purpose of this study is to determine if heart failure subjects whose treatment is
assisted by home BNP measurements integrated into a home health management system will have
better clinical outcomes than subjects whose treatment includes home health management
without BNP or than subjects treated by standard care.
Trial related presentations / publications
Kenneth McDonald, Professor
St Vincent's Private Hospitale Ltd, Dublin, Ireland